NCT07848295Not yet recruitingPhase 1
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
A Phase 1, Multicenter, Open-label, Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Novel Combinations in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to assess the safety and tolerability of BMS-986527 in participants with Clear Cell Renal Cell Carcinoma (ccRCC)
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 112 (estimated)
- First submitted
- 22 Sept 2026
- Start date
- 31 Dec 2026
- Primary completion date
- 18 Oct 2030
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Diseases
- Kidney cancer
- NCT number
- NCT07848295
- EudraCT number
- 2025-522761-29
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 112
- From 31 Dec 2026 to the primary completion date, 18 Oct 2030
- 17 sites in 7 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- For Cohort 2 only: has relapsed or is refractory within 12 months of the most recent IO therapy.
- For Cohort 3 only: use of strong inhibitor and inducers of CYP3A4, and P-glycoprotein (P-gp) substrates within 14 days or 5 half-lives (whichever is longer) of start of TKI.
Age
- Participants must not have prior history of malignancies (other than clear cell renal cell carcinoma (ccRCC)) or lymphoproliferative disease, unless the participant has been free of the disease for ≥ 2 years.
Other
- Other protocol-defined Inclusion/Exclusion criteria apply.
Who the study is looking for
- Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic renal cell carcinoma (RCC) with clear cell component.
- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Participants must have measurable disease as assessed by the Investigator using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
- For Cohorts 1 and 2, participants should have previously received, be refractory to, ineligible for, or intolerant of standard of care (SoC) immunotherapy (IO) and/or tyrosine kinase inhibitors (TKIs). Participants in Cohort 3 should have previously received, be refractory to, ineligible for, or intolerant of SoC IO, but those who have not been previously exposed to SoC TKI agents are permitted.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (17)
Sites in registry order. Save your city in your profile to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.